Stock analysts at Brean Capital began coverage on shares of Cytosorbents Corp (OTCMKTS:CTSO) in a research report issued to clients and investors on Tuesday. The brokerage set a “buy” rating and a $24.00 price target on the stock. Brean Capital’s price target would indicate a potential upside of 309.56% from the stock’s previous close.
Separately, Maxim Group reissued a “buy” rating and set a $8.00 price target on shares of Cytosorbents Corp in a report on Sunday, July 17th.
Cytosorbents Corp (OTCMKTS:CTSO) opened at 5.86 on Tuesday. The firm’s market capitalization is $149.06 million. The stock’s 50 day moving average price is $5.67 and its 200 day moving average price is $4.78. Cytosorbents Corp has a one year low of $3.11 and a one year high of $8.10.
Cytosorbents Corp (OTCMKTS:CTSO) last announced its earnings results on Tuesday, August 9th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $0.03. The firm had revenue of $1.90 million for the quarter, compared to analyst estimates of $2.18 million. Analysts expect that Cytosorbents Corp will post ($0.39) EPS for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Fund Advisors raised its stake in Cytosorbents Corp by 39.3% in the second quarter. BlackRock Fund Advisors now owns 53,915 shares of the company’s stock valued at $245,000 after buying an additional 15,203 shares in the last quarter. Douglass Winthrop Advisors LLC acquired a new stake in Cytosorbents Corp during the second quarter valued at approximately $321,000. Advisor Group Inc. acquired a new stake in Cytosorbents Corp during the second quarter valued at approximately $1,372,000. Raymond James & Associates raised its stake in Cytosorbents Corp by 318.6% in the second quarter. Raymond James & Associates now owns 324,603 shares of the company’s stock valued at $1,477,000 after buying an additional 247,052 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in Cytosorbents Corp by 1.0% in the second quarter. Vanguard Group Inc. now owns 537,707 shares of the company’s stock valued at $2,447,000 after buying an additional 5,446 shares in the last quarter.
About Cytosorbents Corp
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corp and related companies with MarketBeat.com's FREE daily email newsletter.